Topic Hub
216 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 216 of 216 clinical reviews.
A head-to-head review of alirocumab (Praluent) versus losartan across clinical trials and real-world evidence, covering LDL reduction, cardiovascular outcomes, blood pressure control, and when a clinician might prescribe each drug.
Read clinical reviewAtorvastatin (Lipitor) lowers LDL cholesterol and reduces cardiovascular events. Losartan (Cozaar) lowers blood pressure and protects the kidneys. They treat different problems. This guide compares real-world outcomes, mechanisms, dosing, side-effect profiles, and when a clinician might prescribe both.
Read clinical reviewA clinical comparison of rosuvastatin (Crestor) and amlodipine across special populations including elderly patients, diabetics, CKD, and women. Evidence from JUPITER, ASCOT-BPLA, and real-world data with dosing guidance.
Read clinical reviewRosuvastatin (Crestor) and amlodipine treat different cardiovascular risk factors. Learn why doctors combine them, when switching makes no clinical sense, and what the evidence says about safety and drug interactions.
Read clinical reviewA clinical comparison of rosuvastatin (Crestor) and amlodipine for long-term cardiovascular outcomes, durability of LDL and blood-pressure control, and guidance on when switching is appropriate.
Read clinical reviewA clinician-reviewed comparison of rosuvastatin (Crestor) and amlodipine across mechanism, major trials, real-world outcomes, and patient selection, with inline citations to PubMed, FDA, and ACC/AHA guidelines.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and amlodipine titration schedules, side-effect profiles, and cardiometabolic outcomes, reviewed by the HealthRX medical team.
Read clinical reviewRosuvastatin (Crestor) and amlodipine treat different cardiovascular risk factors. This guide explains when each drug fails, why, and exactly what clinicians and patients should do next.
Read clinical reviewRosuvastatin (Crestor) vs inclisiran (Leqvio) across special populations including CKD, diabetes, elderly, and statin-intolerant patients. Evidence-based comparison with trial data, dosing, and switching guidance.
Read clinical reviewA detailed, physician-reviewed comparison of rosuvastatin (Crestor) and inclisiran (Leqvio) using real-world evidence, landmark trials, and current ACC/AHA guidelines to help patients and clinicians decide when to switch or combine therapies.
Read clinical reviewA clinical deep-dive comparing rosuvastatin (Crestor) and inclisiran (Leqvio), explaining why combining both drugs often outperforms either alone, and detailing the real safety risks every patient and prescriber should know.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and inclisiran (Leqvio) examining long-term LDL-C durability, trial data, real-world adherence, and when switching makes clinical sense.
Read clinical reviewA clinical comparison of rosuvastatin (Crestor) and inclisiran (Leqvio) covering titration schedules, LDL-C reduction, side-effect profiles, and when a switch makes sense, reviewed by the HealthRX medical team.
Read clinical reviewRosuvastatin and inclisiran work through completely different mechanisms. When one stops delivering enough LDL-C reduction, the other may be exactly the right next step. This guide explains when and why to switch or combine.
Read clinical reviewRosuvastatin (Crestor) and lisinopril serve different cardiometabolic targets, yet patients often take both. This head-to-head guide covers efficacy, safety, and prescribing decisions across special populations including CKD, diabetes, elderly, and pregnancy.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and lisinopril on long-term cardiometabolic durability, covering trial evidence, real-world persistence, and when switching makes sense.
Read clinical reviewA head-to-head comparison of rosuvastatin (Crestor) and lisinopril using real-world evidence, major clinical trials, and guideline recommendations. Learn which drug treats what, when each is used together, and what switching means clinically.
Read clinical reviewA clinical comparison of rosuvastatin (Crestor) and lisinopril titration protocols, side-effect profiles, and cardiometabolic outcomes, reviewed by the HealthRX medical team.
Read clinical reviewRosuvastatin (Crestor) and lisinopril treat different cardiometabolic risk factors and rarely substitute for each other. Learn when each drug fails, what the evidence says about alternatives, and how to work with your clinician to adjust your regimen.
Read clinical reviewRosuvastatin (Crestor) and losartan target different cardiovascular risk factors. This clinical comparison covers efficacy, safety, and dosing across special populations including CKD, diabetes, elderly, and pregnancy.
Read clinical reviewA clinical comparison of rosuvastatin (Crestor) and losartan for cardiometabolic outcomes, covering durability of LDL lowering, blood pressure control, trial evidence from JUPITER and LIFE, and guidance on switching.
Read clinical reviewRosuvastatin (Crestor) lowers LDL cholesterol. Losartan lowers blood pressure and protects kidneys. They treat different cardiometabolic problems, so most patients who need both should take both. This guide explains the pharmacology, the trial data, and the real clinical situations where combination therapy makes sense.
Read clinical reviewA detailed clinical comparison of rosuvastatin (Crestor) vs losartan titration speed, tolerability, and cardiometabolic outcomes, reviewed by the HealthRX medical team.
Read clinical reviewRosuvastatin (Crestor) vs alirocumab (Praluent) compared across special populations including CKD, diabetes, elderly, and FH patients. Evidence-based guidance on when to switch, combine, or choose one over the other.
Read clinical reviewA clinical deep-dive comparing rosuvastatin (Crestor) and alirocumab (Praluent) for LDL reduction and cardiovascular outcomes, using real-world data, ODYSSEY OUTCOMES, JUPITER, and current ACC/AHA guidelines.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and alirocumab (Praluent) covering long-term durability of LDL-C reduction, cardiovascular outcomes, and when to switch or combine therapies.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and alirocumab (Praluent) covering titration schedules, LDL reduction, tolerability, and when to switch or combine both drugs.
Read clinical reviewRosuvastatin (Crestor) and alirocumab (Praluent) lower LDL-C through different mechanisms. This guide explains when to switch, when to combine, and what the evidence says about outcomes after one agent stops working.
Read clinical reviewA detailed head-to-head comparison of rosuvastatin (Crestor) and evolocumab (Repatha) across special populations including CKD, diabetes, elderly, and statin-intolerant patients. Reviewed by the HealthRX medical team.
Read clinical reviewA head-to-head comparison of rosuvastatin (Crestor) and evolocumab (Repatha) drawing on landmark trials, real-world registries, and current ACC/AHA guidelines to help clinicians and patients decide which LDL-lowering strategy fits their risk profile.
Read clinical reviewA clinician-reviewed comparison of rosuvastatin (Crestor) and evolocumab (Repatha), covering why combining both drugs often beats monotherapy, what the evidence shows, and how to manage real risks.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and evolocumab (Repatha) covering long-term LDL durability, cardiovascular outcomes, safety, and when to consider switching, reviewed by the HealthRX medical team.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and evolocumab (Repatha) covering titration protocols, LDL reduction, side-effect profiles, and when to switch or combine both drugs.
Read clinical reviewRosuvastatin (Crestor) and evolocumab (Repatha) work through different mechanisms and fill different clinical roles. Learn when statin therapy fails, when to add or switch to a PCSK9 inhibitor, and what the evidence says about sequencing these drugs for LDL control and cardiovascular risk reduction.
Read clinical reviewRosuvastatin (Crestor) and ezetimibe (Zetia) lower LDL by different mechanisms. This evidence-based comparison covers efficacy, safety, and dosing in special populations including CKD, elderly, pregnancy, diabetes, and statin-intolerant patients.
Read clinical reviewA physician-reviewed, evidence-based comparison of rosuvastatin (Crestor) vs ezetimibe (Zetia) covering LDL reduction, cardiovascular outcomes, real-world use, and when to switch or combine.
Read clinical reviewA clinical comparison of rosuvastatin (Crestor) vs ezetimibe (Zetia) examining long-term durability of LDL response, cardiovascular outcomes, and when switching makes sense.
Read clinical reviewA head-to-head clinical comparison of rosuvastatin (Crestor) and ezetimibe (Zetia) covering titration protocols, LDL reduction, tolerability, and when to switch or combine.
Read clinical reviewA physician-reviewed comparison of rosuvastatin (Crestor) and ezetimibe (Zetia) covering mechanism, trial evidence, and step-by-step clinical guidance for when one drug stops working or causes intolerable side effects.
Read clinical reviewA clinical comparison of ezetimibe and inclisiran for LDL-C lowering, including the evidence for combining both drugs, safety considerations, and when to switch or stack.
Read clinical reviewAn evidence-based comparison of inclisiran (Leqvio) and amlodipine across special populations including elderly patients, those with CKD, diabetes, and cardiovascular disease. Understand which drug fits which patient.
Read clinical reviewInclisiran (Leqvio) lowers LDL-C via PCSK9 silencing twice a year. Amlodipine controls blood pressure and reduces angina. Learn when combining both drugs makes clinical sense, what the risks are, and whether switching one for the other is ever appropriate.
Read clinical reviewA clinical comparison of inclisiran (Leqvio) and amlodipine for long-term cardiometabolic durability, covering trial data, mechanisms, switching considerations, and practical prescribing guidance.
Read clinical reviewA head-to-head clinical comparison of inclisiran (Leqvio) and amlodipine for cardiometabolic risk reduction, covering mechanisms, trial data, real-world evidence, and which patients benefit most from each drug.
Read clinical reviewA clinical comparison of inclisiran (Leqvio) and amlodipine for cardiometabolic risk reduction, covering titration schedules, tolerability profiles, and which patients benefit most from each drug.
Read clinical reviewInclisiran (Leqvio) and amlodipine target completely different cardiovascular risk factors. Learn when each drug fails, what that failure looks like clinically, and exactly how to adjust your treatment plan.
Read clinical reviewLeqvio (inclisiran) and lisinopril treat different cardiometabolic targets. This guide compares efficacy, safety, and clinical fit across special populations including CKD, diabetes, elderly patients, and more.
Read clinical reviewInclisiran (Leqvio) and lisinopril work through completely different mechanisms, making combination therapy rational for high-risk patients who need both LDL-C reduction and blood pressure control. This guide covers the evidence, dosing, risks, and when to combine or switch.
Read clinical reviewA clinical comparison of inclisiran (Leqvio) and lisinopril for long-term cardiometabolic durability, covering LDL reduction, blood pressure control, trial data, and how to choose between them.
Read clinical reviewA clinical comparison of inclisiran (Leqvio) and lisinopril for cardiometabolic risk reduction, drawing on ORION-10, ORION-11, ALLHAT, and recent real-world registry data.
Read clinical reviewA clinical comparison of inclisiran (Leqvio) and lisinopril covering titration schedules, tolerability profiles, LDL-C vs blood pressure outcomes, and when to use each agent.
Read clinical reviewA clinical comparison of inclisiran (Leqvio) and lisinopril for cardiometabolic management, with evidence-based guidance on switching, combining, or escalating therapy when one agent is not meeting treatment targets.
Read clinical reviewA detailed clinical comparison of inclisiran (Leqvio) and losartan across special populations including CKD, elderly, diabetic, and high-CV-risk patients. Includes trial data, dosing, and switching guidance.
Read clinical reviewA head-to-head clinical comparison of inclisiran (Leqvio) and losartan, explaining why cardiologists combine them, what the evidence shows, and the specific risks patients and prescribers must weigh.
Read clinical reviewA head-to-head clinical comparison of inclisiran (Leqvio) and losartan for long-term cardiometabolic durability, covering LDL-C reduction, blood pressure control, trial evidence, and how to decide between them.
Read clinical reviewAn evidence-based comparison of inclisiran (Leqvio) and losartan across clinical trials and real-world data, covering LDL-C reduction, blood pressure control, dosing, safety, and patient selection.
Read clinical reviewA clinical comparison of inclisiran (Leqvio) and losartan on titration speed, tolerability, LDL-C and blood pressure outcomes, side-effect profiles, and when switching between them makes sense.
Read clinical reviewInclisiran (Leqvio) and losartan treat different cardiometabolic targets. Learn when each drug fails, what the evidence says about switching, and how a HealthRX clinician decides the next step.
Read clinical reviewA clinical head-to-head comparison of atorvastatin (Lipitor) and amlodipine across special populations including CKD, diabetes, elderly patients, and women. Covers mechanism, trials, dosing, and switching guidance.
Read clinical reviewAtorvastatin (Lipitor) and amlodipine serve entirely different purposes. Learn why cardiologists often prescribe them together, what the ASCOT trial proved, and when combining them raises real safety concerns.
Read clinical reviewShowing the first 60 matches. Use search or filters to narrow the library.